Drug Trial Radar · NCT05639114
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
436
Actual
Start
Mar 2, 2023
Primary completion
Mar 26, 2027
Study completion Mar 23, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus
Interventions
IanalumabDrug
ianalumab s.c. monthly or quarterly
PlaceboDrug
placebo s.c. monthly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants on monthly ianalumab achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)Time frame: Week 60
Locations
135 sites in 19 countries. Site status is shown where the registry gives one.
Pinnacle Research Group Llc
Anniston, Alabama
Providence Medical Center
Burbank, California
University of California San Diego
La Jolla, California
Millennium Clinical Trials
Westlake Village, California
University of Colorado
Aurora, Colorado
Yale University School Of Medicine
New Haven, Connecticut
Clinical Res Of W Florida
Clearwater, Florida
GNP Research
Cooper City, Florida
Clinical Research of West Florida Inc
Tampa, Florida
Parris and Associates Rheumatology
Lawrenceville, Georgia
Chicago Clinical Research Inst
Chicago, Illinois
Robert A Hozman MD SC
Skokie, Illinois
Lake Cumberland Rheumatology and In
New Albany, Indiana
Henry Ford Health
Detroit, Michigan
Sahni Rheumatology and Therapy
West Long Branch, New Jersey
Paramount Med Rsrch and Consult LLC
Middleburg Heights, Ohio
University Of Pittsburgh
Pittsburgh, Pennsylvania
Shelby Research LLC
Memphis, Tennessee
Accurate Clinical Research Research
Baytown, Texas
Novel Research LLC
Bellaire, Texas
Accurate Clinical Research
League City, Texas
Epic Medical Research
Red Oak, Texas
Novartis Investigative Site
San Miguel de Tucumán, Argentina
Novartis Investigative Site
San Miguel, Tucumán Province, Argentina
Novartis Investigative Site
Salvador, Brazil
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
Vitória, Espírito Santo, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
Recife, Pernambuco, Brazil
Novartis Investigative Site
Niterói, Rio de Janeiro, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Rousse, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria, Bulgaria
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.